SCHEMBL3562071

SCHEMBL3562071

N#C/C(=C\c1ccc(-n2nccc2C(F)(F)F)cc1)C(=O)c1ccco1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.43
KDM4E B2RXH2 4/20 0.40
KMT2A Q03164 7/20 0.37
ALDH1A1 P00352 5/20 0.37
HTT P42858 2/20 0.37
MEN1 O00255 5/20 0.36
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA4 P22748 1/20 0.35
CA9 Q16790 1/20 0.35
PKM P14618 1/20 0.35
ATM Q13315 1/20 0.35
POLB P06746 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
MAPT P10636 3/20 0.34
HPGD P15428 1/20 0.34
CES2 O00748 1/20 0.34
CES1 P23141 1/20 0.34
KDR P35968 1/20 0.34
NPSR1 Q6W5P4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3562073 1.00 CYP2C9 (0.43) CYP2C9KDM4EKMT2AALDH1A1HTT
SCHEMBL3560131 0.85 ORAI1 (0.40) CYP2C9KDM4EKMT2AALDH1A1HTT
SCHEMBL3564703 0.84 KMT2A (0.53) KDM4EKMT2AALDH1A1MEN1PKM
SCHEMBL3564700 0.84 KMT2A (0.53) KDM4EKMT2AALDH1A1MEN1PKM
SCHEMBL3557131 0.73 CYP2C9 (0.43) CYP2C9KDM4EKMT2AALDH1A1HTT
SCHEMBL3557129 0.73 CYP2C9 (0.43) CYP2C9KDM4EKMT2AALDH1A1HTT
SCHEMBL3557749 0.73 CYP2C9 (0.43) CYP2C9KDM4EKMT2AALDH1A1MEN1
SCHEMBL3557745 0.73 CYP2C9 (0.43) CYP2C9KDM4EKMT2AALDH1A1MEN1
SCHEMBL5594579 0.69 CYP2C9 (0.47) CYP2C9KDM4EKMT2AALDH1A1HTT
SCHEMBL5594581 0.69 CYP2C9 (0.47) CYP2C9KDM4EKMT2AALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7705029-B2 Acrylonitrile derivatives for inflammation and immune-related uses SYNTA PHARMACEUTICALS CORP. (US) 2010-04-27 US disclosed
EP-1732900-A4 ACRYLONITRILE DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS CORP (US) 2007-12-12 EP disclosed
US-20070270478-A1 ACRYLONITRILE DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS CORP. (US) 2007-11-22 US disclosed
US-7202232-B2 Acrylonitrile derivatives for inflammation and immune-related uses SYNTA PHARMACEUTICALS CORP. (US) 2007-04-10 US disclosed
EP-1732900-A2 ACRYLONITRILE DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES Synta Pharmaceuticals Corporation (US) 2006-12-20 EP disclosed
US-20050272699-A1 Acrylonitrile derivatives for inflammation and immune-related uses SYNTA PHARMACEUTICALS CORP. 2005-12-08 US disclosed
WO-2005091752-A2 ACRYLONITRILE DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS CORP. (US) 2005-10-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050272699-A1 Acrylonitrile derivatives for inflammation and immune-related uses IL1B, IL6, TLR4 CYP2C9 1235/4885KDM4E 4711/4885KMT2A 4809/4885
US-20070270478-A1 ACRYLONITRILE DERIVATIVES FOR INFLAMMATION AND IMMUNE-RELATED USES IL1B, IL6, TLR4 CYP2C9 1235/4885KDM4E 4711/4885KMT2A 4809/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.